Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 12/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14601856 | 0.84 | ACHE (0.67) | ACHE | |
| SCHEMBL14601855 | 0.83 | ACHE (0.76) | ACHE | |
| SCHEMBL14601867 | 0.82 | ACHE (0.71) | ACHE | |
| SCHEMBL4501370 | 0.79 | ACHE (0.81) | ACHE | |
| SCHEMBL9096391 | 0.77 | ACHE (0.63) | ACHE | |
| SCHEMBL8825219 | 0.76 | ACHE (0.81) | ACHE | |
| SCHEMBL27398519 | 0.76 | ACHE (0.58) | ACHE | |
| SCHEMBL12013902 | 0.75 | ACHE (0.75) | ACHE | |
| SCHEMBL15599155 | 0.75 | ACHE (0.74) | ACHE | |
| SCHEMBL9096850 | 0.75 | ACHE (0.76) | ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070021397-A1 | Neurocyte protective agent | EISAI CO., LTD. (JP) | 2007-01-25 | — | — | US | disclosed |
| US-20070021397-A1 | Neurocyte protective agent | EISAI CO., LTD. (JP) | 2007-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021397-A1 | Neurocyte protective agent | CHAT, GAP43, NES | ACHE 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.